BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) have been assigned an average rating of “Moderate Buy” from the twenty-two analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and twenty-one have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $76.25.

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a research note on Wednesday, October 8th. Sanford C. Bernstein started coverage on shares of BridgeBio Pharma in a report on Thursday, December 11th. They set an “outperform” rating and a $94.00 price objective on the stock. Piper Sandler lifted their target price on shares of BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. TD Cowen boosted their target price on shares of BridgeBio Pharma from $60.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, The Goldman Sachs Group upped their price target on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th.

BridgeBio Pharma Stock Up 2.9%

Shares of BridgeBio Pharma stock opened at $76.30 on Monday. The firm has a market cap of $14.70 billion, a PE ratio of -18.25 and a beta of 1.26. BridgeBio Pharma has a twelve month low of $26.02 and a twelve month high of $77.20. The business has a 50-day moving average price of $66.10 and a 200 day moving average price of $54.21.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Wednesday, October 29th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The business had revenue of $120.70 million during the quarter, compared to the consensus estimate of $107.71 million. The company’s revenue for the quarter was up 4318.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.86) earnings per share. On average, sell-side analysts expect that BridgeBio Pharma will post -3.67 EPS for the current year.

Insider Buying and Selling at BridgeBio Pharma

In other news, Director Andrew Lo sold 55,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $65.69, for a total value of $3,612,950.00. Following the transaction, the director owned 50,583 shares in the company, valued at $3,322,797.27. This trade represents a 52.09% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Frank Mccormick sold 198,359 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $66.58, for a total value of $13,206,742.22. Following the completion of the sale, the director directly owned 679,979 shares in the company, valued at $45,273,001.82. This represents a 22.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 587,215 shares of company stock valued at $38,801,501. 18.20% of the stock is owned by insiders.

Institutional Investors Weigh In On BridgeBio Pharma

A number of large investors have recently modified their holdings of BBIO. Strs Ohio increased its holdings in shares of BridgeBio Pharma by 1.1% during the 3rd quarter. Strs Ohio now owns 18,600 shares of the company’s stock worth $966,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC increased its stake in BridgeBio Pharma by 28.6% during the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock worth $53,000 after acquiring an additional 227 shares during the last quarter. Steward Partners Investment Advisory LLC increased its stake in BridgeBio Pharma by 22.3% during the second quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock worth $54,000 after acquiring an additional 228 shares during the last quarter. Gabelli Funds LLC raised its position in BridgeBio Pharma by 0.3% in the second quarter. Gabelli Funds LLC now owns 73,750 shares of the company’s stock valued at $3,185,000 after purchasing an additional 250 shares during the period. Finally, First Bank & Trust lifted its stake in shares of BridgeBio Pharma by 3.9% in the 2nd quarter. First Bank & Trust now owns 8,822 shares of the company’s stock valued at $381,000 after purchasing an additional 329 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.